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Abstract
Expansion of the lysosomal system, including cathepsin D upregulation, is an early and prominent finding in Alzheimer’s
disease brain. Cell culture studies, however, have provided differing perspectives on the lysosomal connection to
Alzheimer’s disease, including both protective and detrimental influences. We sought to clarify and molecularly define the
connection in vivo in a genetically tractable model organism. Cathepsin D is upregulated with age in a Drosophila model of
Alzheimer’s disease and related tauopathies. Genetic analysis reveals that cathepsin D plays a neuroprotective role because
genetic ablation of cathepsin D markedly potentiates tau-induced neurotoxicity. Further, generation of a C-terminally
truncated form of tau found in Alzheimer’s disease patients is significantly increased in the absence of cathepsin D. We
show that truncated tau has markedly increased neurotoxicity, while solubility of truncated tau is decreased. Importantly,
the toxicity of truncated tau is not affected by removal of cathepsin D, providing genetic evidence that modulation of
neurotoxicity by cathepsin D is mediated through C-terminal cleavage of tau. We demonstrate that removing cathepsin D in
adult postmitotic neurons leads to aberrant lysosomal expansion and caspase activation in vivo, suggesting a mechanism
for C-terminal truncation of tau. We also demonstrate that both cathepsin D knockout mice and cathepsin D–deficient
sheep show abnormal C-terminal truncation of tau and accompanying caspase activation. Thus, caspase cleavage of tau
may be a molecular mechanism through which lysosomal dysfunction and neurodegeneration are causally linked in
Alzheimer’s disease.
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Introduction
Tauopathies, including Alzheimer’s disease, are characterized
by abnormal intraneuronal accumulation of the microtubule-
associated protein tau. The identification of dominant mutations
in the gene encoding tau in hereditary tauopathies (frontotemporal
dementia with Parkinsonism linked to chromosome 17; FTDP-17)
has established a causal relationship between tau and neurode-
generation. Interestingly, lysosomal alterations also accompany
these complex neurodegenerative disorders. Lysosomes are
responsible for autophagy, mediating proteolysis and recycling of
cellular and endocytosed materials, and their degradative activities
depend critically upon the cathepsin proteases [1]. Application of
anti-cathepsin antibodies to Alzheimer’s disease brain has revealed
widespread expansion of the lysosomal system early in Alzheimer’s
disease. The increased numbers and density of structurally
abnormal lysosomes found in Alzheimer’s disease neurons is
specific for affected brain regions [2,3]. Similar changes occur in
Alzheimer’s disease rodent models, including mice in which
mutant tau is overexpressed [4].
Striking loss of neurons in a number of inherited, predom-
inantly pediatric lysosomal storage disorders reveals neuronal
vulnerability to lysosomal dysfunction [1]. However, the role of
lysosomal abnormalities in adult neurodegenerative disorders,
including tauopathies and Alzheimer’s disease, remains unclear.
Broadly, there are three distinct, although not entirely mutually
exclusive, views. First, defective lysosomal function could lead to
accumulation of the proteins implicated in pathologic Alzhei-
mer’s disease aggregates, beta-amyloid and tau, through
abnormal proteolytic processing [3]. Lysosomal proteases have
been shown, for example, to degrade tau in vitro and in cultured
cells [5,6]. Second, lysosomal dysfunction could indirectly
promote neurodegeneration through abnormal permeabiliza-
tion of the lysosome. Decreased stability of lysosomal mem-
branes occurs downstream of a variety of cytotoxic stressors and
leads to the release of lysosomal contents and caspase-dependent
apoptosis [7]. Alternatively, it has been suggested that lysosomal
expansion could be a cytoprotective response in Alzheimer’s
disease, directly facilitating the degradation of toxic proteins via
autophagy [8].
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Alzheimer’s disease, there is conspicuous upregulation of mRNA
and protein of the aspartyl protease cathepsin D within
degenerating neurons [9,10]. Polymorphisms in the cathepsin D-
encoding gene CTSD have also been associated with Alzheimer’s
disease [11,12]. The discovery that mutations in cathepsin D cause
aggressive neurodegeneration in one form of neuronal ceroid
lipofuscinosis, a childhood neurodegenerative lysososomal storage
disease [13,14] has suggested upregulation in Alzheimer’s disease
may be a compensatory protective response. In contrast, other
studies have suggested that cathepsin D can act a pro-apoptotic
molecule [15]. Still other work suggests a direct relationship
between tau and cathepsins, showing cathepsin inhibition
promotes tau accumulation and post-translational modifications
including phosphorylation [16].
To investigate the role of lysosomal expansion and cathepsin D
in tauopathies, we employed a genetically tractable in vivo
approach. As in Alzheimer’s disease, microarray analysis of a
well-characterized Drosophila model of tauopathy identified lyso-
somal dysfunction and cathepsin D upregulation. Genetic ablation
of cathepsin D caused lysosomal expansion and caspase activation,
and markedly potentiated tau-induced toxicity. The latter effect
depended upon caspase-directed cleavage of tau that generated a
toxic C-terminally truncated tau species. Furthermore, cathepsin
D deficiency in mice and sheep also led to caspase activation and
C-terminal truncation of tau. Our results suggest that caspase
cleavage of tau is a molecular target of lysososomal dysfunction in
Alzheimer’s disease and possibly other human neurodegenerative
disorders.
Results
Removing cathepsin D specifically enhances tau-induced
neurodegeneration and cell-cycle activation
In flies, neuronal expression of human tau, whether wild-type or
mutant forms linked to hereditary tauopathies (FTDP-17), causes
apoptotic neurodegeneration with brain vacuolization and TU-
NEL labeling of neurons [17,18,19]. Expression of mutant
tau
R406W induces a level of toxicity well suited for genetic analysis
[17,18,20]. The R406W mutant form of tau is thus used primarily
in the current paper, and is termed ‘‘tau’’ for simplicity. In an
unbiased, genome-wide expression analysis of aging tau transgenic
flies, we previously observed significant changes in the expression
of lysosomal genes suggestive of general lysosomal dysfunction in
our model [21]. Cathepsins, including cathepsin D, are lysosomal
enzymes that are evolutionarily conserved from Drosophila to
humans [22]. Here we confirmed prominent cathepsin D
overexpression in the tauopathy model at early and advanced
disease stages compared to age-matched control animals using
quantitative PCR (fold-change, 1.6 with P=0.005, and 2 with
P=0.037, respectively; Figure S1), thus recapitulating findings
from Alzheimer’s disease patients. These data provide a rationale
for determining the effect of genetically modulating cathepsin D
levels on tau-induced neurodegeneration. Conveniently, complete
removal of cathepsin D in flies is not lethal [22]. Tau transgenic
flies were accordingly crossed into a cathepsin D null background.
As previously reported, flies overexpressing tau exhibit reduced
lifespan compared to control animals [19]. Removing cathepsin D
further reduced the longevity of tau transgenic flies by almost 50%,
while deletion of cathepsin D on a wild-type background had no
clear effect (Figure 1A).
To establish whether the decrease in lifespan correlated with
increased neurotoxicity, we determined the degree of apoptotic
cell death by counting the number of TUNEL-positive neurons in
brain sections. As previously described, non-transgenic and
cathepsin D null control flies exhibited negligible TUNEL-
positivity at 10 days [22], while neuronal death in tau transgenic
flies was detected by TUNEL staining [18] (Figure 1B). Consistent
with the lifespan data, flies expressing tau in a cathepsin D null
mutant background showed an almost 3-fold increase in apoptotic
cell death (Figure 1B). A similar effect on neurodegeneration was
revealed by histological analysis and subsequent quantification of
vacuolar degeneration in aged fly brains (Figure 1C). Together,
these data suggest reduction in cathepsin D significantly promotes
tau-induced neurodegeneration in vivo.
We have previously shown that tau-induced cell cycle reentry
mediates neuronal apoptosis in the fly tauopathy model [18], a result
that has been corroborated in rodent models model of tauopathy
[23,24]. To test whether removal of cathepsin D enhanced tau-
induced neurodegeneration through abnormal cell-cycle activation,
we immunostained brains from 10-day-old flies for proliferating cell
nuclear antigen (PCNA), an S-phase cell-cycle marker abnormally
upregulated in brains of Alzheimer’s disease patients and tau-
expressing flies. As for TUNEL, removal of cathepsin D markedly
increased PCNA staining (approximately 3 fold) in flies expressing
tau in cathepsin D-deficient genetic background (Figure 1D). Non-
transgenic and cathepsin D null control flies were immunonegative
for PCNA. These results suggest that cathepsin D modulation of tau
toxicity occurs via abnormal cell-cycle re-entry.
The human disease literature suggests that early lysosomal
abnormalities, including cathepsin D upregulation, are particularly
prominent in Alzheimer’s disease compared to other adult-onset
neurodegenerative disorders [3]. We have previously characterized
degeneration of postmitotic neurons in a fly model of Machado-
Josephdisease(spinocerebellarataxiatype3),anautosomaldominant
neurodegenerative disease caused by polyglutamine expansion within
the protein ataxin3. Panneural expression of mutant human ataxin 3
in Drosophila causes age-dependent neurodegeneration [25,26], as
quantified by decreased numbers of Kenyon cells in the mushroom
body [25]. Removing cathepsin D from mutant ataxin 3 overex-
pressing flies had no effect on Kenyon cell loss (Figure S2), suggesting
that removal of cathepsin D is not generally toxic in neurodegen-
erative disease models.
Author Summary
Neurodegenerative disorders, like Alzheimer’s disease, are
a devastating group of conditions that exact a heavy toll
on patients and their families. These disorders also
represent a significant and growing public health chal-
lenge as our population ages because no effective
treatments are available. Research over the past two
decades has strongly suggested that a fundamental
problem in affected nerve cells relates to accumulation
of cellular ‘‘garbage,’’ or proteins and other material that is
too old to function properly. Thus, understanding how the
neuron handles these outdated molecules is of great
significance. Here we find that upregulation of one such
cellular degrading pathway, the lysosome, can have
significant deleterious effects to the neuron. We specifi-
cally show that expanding the lysosomal compartment can
markedly increase production of a very toxic form of tau, a
protein strongly implicated in neuronal dysfunction and
death in Alzheimer’s disease and related disorders. Our
findings have important implications for the development
of neurodegenerative disease therapies that seek to
manipulate the lysosome and the proteins within the
lysosome.
Lysosomal Dysfunction in Tauopathy
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tau phosphorylation
Since cathepsins have implicated in tau degradation, reduction
of cathepsin D could potentiate tau toxicity by increasing total
levels of tau. However, Western blots did not reveal an increase in
tau levels in our model (Figure 2A). We next looked at potential
post-translational modifications of tau that promote neurodegen-
eration. Tau hyperphosphorylation is a common post-translational
modification in human tauopathies, and tau phosphorylation
promotes neurodegeneration in Drosophila [27,28,29]. Analysis of
adult fly head homogenates by Western blotting did not, however,
reveal any appreciable change in tau phosphorylation at a number
of disease-associated phosphoepitopes (AT8, TG3, PHF-1,
AT180, AT270; Figure 2B). Enhancement of tau-induced
neurodegeneration observed in cathepsin D-deficient flies thus
did not appear to be mediated by an increase in total tau levels or
tau phosphorylation.
Removal of cathepsin D increases caspase-cleaved tau,
which colocalizes with activated caspase-3
The pharmacologic inhibition of cathepsins in hippocampal
slice culture has been shown to promote cytosolic proteolysis of tau
[30], Cleavage at one particular proteolytic site, the
418DXXD
421
canonical caspase site, has been shown to occur in human
tauopathies [31,32,33]. Caspase-3 is one of the key executioners of
apoptosis in mammals, with homologous proteases in Drosophila
including Drice and DCP-1. The caspase 3-cleaved form of tau,
truncated at D421, is toxic in cell culture [34,35,36] and
fibrillogenic in vitro [31,33]. To address whether genetic loss of
cathepsin D promotes tau proteolysis in transgenic flies, levels of
truncated tau were analyzed using a monoclonal antibody specific
to caspase cleaved tau, tau-C3 [31]. The scattered tau-C3-
immunopositive staining observed in brain sections from trans-
genic tau flies was increased approximately 5-fold in the absence of
cathepsin D (Figure 3A–3C, Figure S3). Western blot confirmed
the elevation in C-terminally truncated tau in cathepsin D mutants
(Figure 3D, Figure S4).
To determine if tau truncation could be linked to caspase
activation, we used an antibody recognizing cleaved caspase-3 to
assess caspase activation in fly brains. This antibody detects a
fragment of activated caspase-3, and also labels dying cells in
Drosophila where it may specifically recognize the effector caspase
Drice [37,38]. We used the antibody to confirm the presence of
activated caspase-positive neurons in the brains of tau transgenic
flies in the presence of absence of cathepsin D. Activated caspase
Figure 1. Neurotoxicity of human tau is markedly increased in the absence of cathepsin D. (A) Lifespan of tau transgenic flies is shortened
in a cathepsin D null background. (B,C) Neurodegeneration, as indicated by the number of TUNEL-positive cells (B) or vacuoles (C) is significantly
increased in tau transgenic flies in a cathepsin D null background. (D) Cell cycle activation, as indicated by PCNA immunostaining, is significantly
increased by removing cathepsin D. *indicates P,0.01, one-way ANOVA with Student-Neuman-Keuls post hoc test for multiple comparisons. Flies are
10 days old. Control is elav-GAL4/+ in all panels.
doi:10.1371/journal.pgen.1001026.g001
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activation underlying the increased tau-C3 staining in cathepsin
D-deficient tau transgenic animals (Figure 4A). No immunoreac-
tivity for activated caspase was observed in control animals (elav-
GAL4/+, 10 days-of-age; data not shown). We have previously
demonstrated that tau-induced cell-cycle activation is down-
stream of tau phosphorylation and directly precedes apoptosis
[18]. Interestingly, we also observed significant colocalization
between tau-C3 and PCNA (Figure 4B). Control fly brains (elav-
GAL4/+, 10 days-of-age) do not show expression of PCNA
[17,18]. The aberrant activation of cell cycle in neurons
containing truncated tau strengthens the linkage between
caspase-directed cleavage of tau and neuronal degeneration
through abnormal cell cycle activation.
Caspase-cleaved tau has increased toxicity, which is not
altered by removing cathepsin D
Given the robust increase in C-terminally truncated tau
following removal of cathepsin D, we characterized the effects of
C-terminal truncation in vivo. The fly tauopathy model provides an
opportunity to compare directly the toxicity of different forms of
tau in vivo. We thus generated a transgenic Drosophila line
expressing wild-type human tau truncated at Asp-421 (tau
1–421)
and compared the effect of its expression in the fly brain to that of
full-length wild-type tau (tau
WT). We chose to examine truncation
of tau in the context of the wild-type protein, rather than the
FTDP-17 linked R406W form of tau previously used in the paper
because truncation of tau has been most extensively characterized
in the context of wild-type tau [31,32,33]. The highest expressing
lines of tau
1–421 we recovered expressed significantly less tau
compared to our tau
WT control lines (Figure 5A). Serial dilution
experiments revealed that tau
1–421 was expressed at approximately
20% of tau
WT levels (data not shown). Nonetheless, the number of
TUNEL-positive neurons in the brains of flies expressing tau
1–421
was significantly higher than in tau
WT-expressing flies (by
approximately 8 fold; compared number of TUNEL-positive cells
in Figure 5B), establishing that caspase-cleaved tau is considerably
more toxic in vivo than wild-type tau. Just as we showed for
tau
R406W, removal of cathepsin D potentiated the toxicity of tau
wt
(by approximately 4 fold). Unlike wild-type tau, however,
removing cathepsin D did not enhance the toxicity of tau
1–421
(Figure 5B). The inability of cathepsin D removal to alter the
toxicity of caspase-cleaved tau places C-terminal cleavage of tau
downstream of cathepsin D.
Previous studies have demonstrated that C-terminal truncation
of tau promotes fibrillization in vitro [31,39,40]. We therefore
assessed the solubility of tau in our in vivo system. Consistent with
the in vitro studies, we found a substantially higher fraction of
nonionic detergent-insoluble tau in the brains of tau
1–421 animals
compared to tau
WT transgenics (Figure 5C and 5D, Figure S5,
Figure S6). Together with the finding of increased C-terminally
truncated tau in the cathepsin D null background (Figure 3), our
data mechanistically link the formation of the less soluble and
Figure 2. Removing cathepsin D does not substantially alter
levels of tau. (A) No clear alteration in the levels of tau as monitored
by a phosphorylation-independent antibody in cathepsin D mutant
animals. The blot was reprobed for actin to document equivalent
protein loading (bottom panel). (B) No clear changes in levels of tau
phosphorylated at a variety of disease-associated residues in the
absence of cathepsin D. The blot was reprobed with a phosphorylation-
independent anti-tau antibody to ensure equivalent loading (bottom
panel, Total tau). Flies are 10 days old. Control is elav-GAL4/+.
doi:10.1371/journal.pgen.1001026.g002
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modulation of neurotoxicity by cathepsin D.
Loss of cathepsin D results in caspase-dependent
cleavage of PARP and expansion of the lysosomal
compartment
Our data suggested that loss of cathepsin D potentiates tau-
induced neurotoxicity via caspase-dependent C-terminal trunca-
tion of tau (Figure 3, Figure 4). To further probe activation of
caspase in our system we employed a genetically encoded reporter
construct. Transgenic flies have been created that express a
caspase substrate, human poly-ADP-ribose polymerase-1 (PARP).
Human PARP is cleaved by mammalian caspase-3 and by
homologous Drosophila effector caspases. The construct contains 40
amino acids of PARP, including the caspase cleavage site, and the
Venus reporter that can be recognized by an antibody to GFP
[41]. The smaller cleaved product can be detected by mobility
shift on Western blot. Utilizing this reporter, we found a significant
increase in cleaved PARP in fly brains after genetic deletion of
cathepsin D (Figure 6A), strongly suggesting that reducing
cathepsin D levels led to caspase activation.
We next investigated the mechanism through which removal of
cathepsin D leads to caspase activation. A number of studies have
shown that lysosomal abnormalities can lead to destabilization and
increased permeability of the lysosomal membrane. Lysosomal
proteases then activate a proteolytic cascade leading to caspase
activation and apoptosis [7,15]. We have previously shown
accumulation of lysosomal storage material in cathepsin D null
flies [22]. Together with the known early expansion of the
lysosomal compartment within dying neurons in Alzheimer’s
disease [3] and proliferation of lysosomes after cathepsin inhibition
in hippocampal slice culture [30] these data provided a rationale
for testing whether similar lysosomal abnormalities occurred in the
cathepsin D null flies. Accordingly, whole mount fly brains were
dissected, stained with lysotracker, and examined by confocal
microscopy for lysosomal abnormalities. Compared to control
brains, cathepsin D null flies displayed a significant enlargement of
individual lysosomes, and proliferation of the lysosomal compart-
ment, with single cells sometimes containing multiple large
lysosomes (Figure 6C–6F). To further examine the lysosomal
compartment in our cathepsin D mutant animals, we used
quantitative Western blot analysis to assess the levels of a GFP-
tagged intralysosomal protease, cysteine protease-1 (Cp-1). We
found a marked increase in the levels of Cp-1 in cathepsin D null
animals compared to controls (Figure 6B). These data, together
with our prior analysis of cathepsin D mutant flies [22],
demonstrate that removing cathepsin D leads to striking lysosomal
abnormalities that plausibly underlie the caspase activation
induced by removal of cathepsin D.
Figure 3. C-terminally truncated tau is elevated when cathepsin D is absent. (A,B) Increased levels of C-terminally truncated tau as detected
by immunofluorescence in sections of fly brains from tau transgenic animals (B), as compared with controls (A) using the monoclonal antibody tau-
C3, which specifically recognizes tau truncated at D421. Scale bars are 20 mm. (C) Quantitative analysis of immunostained sections reveals a signicant
increase in the number of neurons containing truncated tau. *indicates P,0.01, one-way ANOVA with Student-Neuman-Keuls post hoc test for
multiple comparisons. (D) Immunoblotting using the tau-C3 antibody to recognize truncated tau also demonstrates increased levels of truncated tau
in cathepsin D mutant tau transgenic flies. The blot was reprobed with a polyclonal antibody recognizing tau to ensure equivalent loading (bottom
panel, tau). Flies are 10 days old. Control is elav-GAL4/+.
doi:10.1371/journal.pgen.1001026.g003
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accumulation of caspase-cleaved tau in cathepsin D
mutant mice and sheep
Loss of cathepsin D results in an aggressive form of the
lysosomal storage disease neuronal ceroid lipofuscinosis in human
patients [13,14]. Similarly, both sheep and mice lacking cathepsin
D activity recapitulate the aggressive neurodegeneration in the
central nervous system, marked expansion of lysosomal compart-
ment and autofluorescent lysosomal storage material found in the
human disease [42,43]. We thus asked whether loss of cathepsin D
in these models leads to caspase activation, as predicted by our
findings in the fly model. We found that in both mouse and sheep
models of cathepsin D deficiency, there were activated caspase-3
immunopositive neurons throughout the cortex (Figure 7A,
arrows). Activated caspase was not seen in cortical sections from
control animals. Importantly, activated caspase was accompanied
by C-terminally truncated tau, as detected by immunostaining
with the tau-C3 monoclonal antibody (Figure 7B, arrows). Some
tau-C3-positive cells displayed dense, punctate staining consistent
with inclusion formation (Figure 7B, arrowhead). Thus, in
mammalian models, just as in flies, removal of cathepsin D leads
to caspase activation and cleavage of tau at Asp-421.
Discussion
Almost two decades ago Cataldo and Nixon described early and
striking lysosomal upregulation in susceptible and dying neurons in
Alzheimer’s disease [44]. Their data raised the possibility of an
important lysosomal contribution to Alzheimer’s disease and other
neurodegenerative diseases. Indeed, the presence of an entire class
of neurodegenerative diseases caused by lysosomal dysfunction,
the lysosomal storage diseases, has emphasized the dependence of
postmitotic neurons, as well as other cell types, on an intact
lysosomal system [45,46]. However, the precise mechanisms by
which lysosomal abnormalities may contribute to neurodegener-
ation in Alzheimer’s disease and related tauopathies have
Figure 5. Truncation of tau significantly increases neurotoxic-
ity and decreases solubility in vivo. (A) Lower levels of tau
1–421
compared to tau
WT. The blot was reprobed for actin to document
equivalent protein loading (bottom panel). Control is elav-GAL4/+. (B)
Neurodegeneration, as indicated by the number of TUNEL-positive cells,
is significantly elevated tau
1–421 in transgenic flies compared to tau
WT,
despite expression at lower levels. Removing cathepsin D significantly
enhances the toxicity of tau
WT, but not of tau
1–421. *indicates P,0.01,
one-way ANOVA with Student-Neuman-Keuls post hoc test for multiple
comparisons. (C,D) Solubility of tau
1–421 is reduced compared to tau
WT,
as evidenced by preferential recovery of tau
1–421 in the insoluble
fraction (D) following detergent solubilization and differential centrifu-
gation. Flies are 10 days old.
doi:10.1371/journal.pgen.1001026.g005
Figure 4. Truncated tau co-localizes with markers of cellular
injury. (A) Immunoreactivity for truncated tau as detected with the
tau-C3 monoclonal antibody (red) colocalizes with activated caspase
(green). Arrows indicate colocalization. (B) Truncated tau (tau-C3, red) is
found in neurons also expressing the cell cycle marker PCNA (green).
Arrows indicate colocalization. Flies are 10 days old.
doi:10.1371/journal.pgen.1001026.g004
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lysosomal system described in dystrophic neurites on tau
aggregated in somatodendritic compartments has not been clear.
To further investigate the connection between the lysosomal
system and Alzheimer’s disease pathogenesis, we have used a
genetically tractable in vivo model system. Our data support a
Figure 6. Widespread lysosomal abnormalities in cathepsin D deficient brains. (A) Cleavage of a transgenic PARP-GFP fusion protein is
increased in cathepsin D mutant flies as revealed by immunoblotting with an anti-GFP antibody. The blot was reprobed for actin to document
equivalent protein loading (bottom panel). (B) The levels of a GFP tagged lysosomal protease, Cp1-GFP, are markedly increased in cathepsin D
mutants, as assessed by immunoblotting with an anti-GFP antibody. The blot was reprobed for actin to document equivalent protein loading
(bottom panel). (C-F) Lysotracker staining confirms widespread expansion of the lysosomal system in cathepsin D deficient brains (E,F) compared with
controls (C,D). Enlargement of lysosomes can be appreciated at higher power (C9–F9, arrows). No clear abnormalities in lysosomes were produced by
the expression of tau in the presence (D,D9) or absence (F,F9) of cathepsin D. Scale bars in (C–F) are 20 mm. Scale bars in (C9–F9) are 5 mm. Control is
elav-GAL4/+ in all panels. Flies are 10 days old.
doi:10.1371/journal.pgen.1001026.g006
Figure 7. Caspase activation and truncation of tau in mammalian models of cathepsin D deficiency. (A) Caspase activation is present in
the cortex of mice (upper panels, arrows) and sheep (lower panels, arrow) lacking cathepsin D, but not in controls. (B) C-terminally truncated tau as
detected with the specific antibody tau-C3 is also found in cathepsin D mutant mice (upper panels, arrow) and sheep (lower panels, arrow), but not in
controls. Arrowhead indicates dense staining, consistent with inclusion formation. Scale bar (A) is 10 mm and applies to all panels.
doi:10.1371/journal.pgen.1001026.g007
Lysosomal Dysfunction in Tauopathy
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Alzheimer’s disease and related tauopathies.
Cathepsin D is an important modulator of tau-induced
neurotoxicity in Alzheimer’s disease and the fly
tauopathy model
The early papers demonstrating lysosomal abnormalities in
Alzheimer’s disease brain demonstrated upregulation of cathepsin
D mRNA and protein in dying neurons in the disease [2]. The
connection between Alzheimer’s disease and cathepsin D has also
been made in multiple additional studies, including investigations
of patient brain tissue, cerebrospinal fluid, fibroblasts, and genetic
studies [9,11,12,47,48]. A number of genetic linkage studies have
suggested a role for cathepsin D in the pathogenesis of Alzheimer’s
disease, although these results have not been replicated in all
cohorts examined, including recent genome wide association
studies [49,50]. Nonetheless, a recent candidate gene analysis in a
large population-based cohort study as well as a meta-analysis of
previous studies supports the association of a CTSD variant and
Alzheimer’s disease risk [51].
The complete loss of cathepsin D in patients results in a
devastating form of the lysosomal neurodegenerative disorder,
neuronal ceroid lipofuscinosis [13,14,52]. Furthermore, cathepsin
inhibition in hippocampal slice and cell culture studies has
previously been shown to affect tau proteolysis and solubility
[5,30]. We therefore determined whether cathepsin D downreg-
ulation could influence tau-induced neurotoxicity in an animal
model of Alzheimer’s disease and related tauopathies. We found
that removing cathepsin D substantially potentiated tau-induced
neurotoxicity, strongly supporting a role for cathepsin D and the
normal lysosomal system in maintaining the viability of postmitotic
neurons. Removing cathepsin D genetically had no effect on
neurotoxicity in a distinct Drosophila model of neurodegenerative
disease in which the polyglutamine-expanded SCA3 protein is
over-expressed, supporting specificity of the effect.
Caspase-cleaved tau links lysosomal dysfunction to tau-
induced neurotoxicity
A number of different hypotheses have related cathepsin
dysregulation to Alzheimer’s disease. In vitro, cathepsins can cleave
proteins believed to be toxic in neurodegenerative diseases,
including tau [8]. In our fly model, however, the marked increase
in tau toxicity in a cathepsin D null genetic background was not
accompanied by a change in tau levels (Figure 2). Tau
phosphorylation is a well-described post-translational modification
in tauopathies, including Alzheimer’s disease, and plays a critical
role in mediating tau neurotoxicity in Drosophila [27,28,29], but
there was no change in tau phosphoepitope levels to explain the
modulatory effect of cathepsin D (Figure 2).
We next directed our attention to levels of the C-terminally
truncated, caspase-cleaved form of tau that is specifically identified
by the tau-C3 monoclonal antibody. Truncated tau has been
implicated in the pathogenesis of Alzheimer’s disease and related
tauopathies because the C-terminally cleaved protein is found in
neurofibrillary lesions (neurofibrillary tangles and neuritic threads)
in Alzheimer’s disease and related tauopathies [31,32,33]. C-
terminal truncation of tau also occurs in murine models of
tauopathy, where caspase activation correlates with neurofibrillary
tangle formation [53]. Further, C-terminally truncated tau has
significant toxicity in cultured neurons [34,35,36]. We found that
cathepsin D removal markedly increased levels of C-terminally
truncated tau (Figure 3). Truncated tau appeared in a restricted
number of neurons (Figure 3, Figure S3), making it difficult to
evaluate the total cytosolic concentration of the C-terminally
truncated species. Since neurons containing truncated tau also
immunostained preferentially for the cell cycle marker PCNA
(Figure 4B), it is possible that C-terminal truncation of tau is a
relatively late event that leads to cell cycle activation and
subsequent neuronal apoptosis. Importantly, tau-induced caspase
activation co-immunolocalized with tau-C3, supporting a role for
activated caspase in the generation of truncated tau in our in vivo
system (Figure 4A). We further verified that tau
1–421, when
expressed in flies, was substantially more toxic and less soluble
than wild-type tau. Utilizing the power of Drosophila genetics, we
demonstrated that, unlike the case for wild-type tau, the toxicity
induced by tau
1–421 was not exacerbated by removal of cathepsin
D (Figure 5B). This genetic result established a causal role for C-
terminal truncation of tau in the exacerbation of tau neurotoxicity
by removal of cathepsin D in our model system.
Lysosomal dysfunction offers an attractive link between
cathepsin D depletion and caspase-dependent cleavage of tau for
several reasons. First, abnormal expansion of the lysosomal system
is well described in Alzheimer’s disease brain, as noted above, and
cathepsins are critical components of the lysosome. Second, loss of
cathepsin D function in humans causes marked lysosomal
proliferation, abnormal accumulation of lysosomal storage mate-
rial and aggressive neurodegeneration in an infantile form of
neuronal ceroid lipofuscinosis [13,14,52]. Third, lysosomal
dysfunction is known to lead to abnormal lysosomal permeability,
release of lysosomal contents and subsequent cytosolic activation
of caspases [7]. Supporting this model, we demonstrate that loss of
cathepsin D leads to abnormal intraneuronal lysosomal expansion
in the adult fly brain and an increase in caspase activity (Figure 6).
Interestingly, oxidative stress, a well-described trigger of increased
lysosomal permeability and implicated both in Alzheimer’s disease
and in our Drosophila tauopathy model [17], may be a potential
contributor to the marked increase in tau toxicity observed in the
cathepsin D null background.
Caspase-mediated tau cleavage and lysosomal
dysfunction: unifying mechanisms of toxicity in diverse
brain diseases?
A variety of neurodegenerative conditions have been associated
with neurofibrillary tau pathology, ranging from repeated head
trauma to abnormal prion protein accumulation [54]. Of
particular relevance to the current study, tau aggregation is also
an invariant pathology in certain lysosomal disorders, most
notably Niemann Pick Type C. The prototypic ‘‘secondary’’
tauopathy is, of course, Alzheimer’s disease in which abnormal
amyloid precursor protein processing and beta-amyloid accumu-
lation is considered the inciting event, and tau aggregation an
essential downstream mediator of neurotoxicity [55]. The
existence of primary tauopathies, particularly tauopathies caused
by mutations in MAPT (FTDP-17) [56,57,58], make it improbable
that tau abnormalities are bystander events in these multiple
disorders that exhibit neurofibrillary pathology.
In Alzheimer’s disease there is considerable experimental
support for an important role of tau in the pathogenesis of the
disease. For example, experiments in a variety of animal models
have demonstrated synergistic effects of tau and beta-amyloid on
protein aggregation and neurodegeneration [20,59,60]. In an
elegant recent study, toxicity produced by expression of human
amyloid precursor protein in a mouse model of Alzheimer’s
disease was completely blocked by removing endogenous mouse
tau [61]. Importantly, the same study demonstrated that removing
endogenous mouse tau also protected from excitotoxin-induced
seizures, even in the absence of human amyloid precursor protein
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even in the absence of fibrillary tau pathology.
A number of studies suggest that various upstream inciting
neurotoxic factors promote neurotoxicity and neuronal cell loss via
post-translational modifications of tau. While considerable atten-
tion has been directed to phosphorylation of tau, our data support
a growing literature implicating C-terminally truncated tau as a
critical downstream effector. Caspase cleavage of tau has been well
documented in postmortem brain tissue from patients with
Alzheimer’s disease, and truncated tau shows significant toxicity
in cultured cells. As noted above, in this study we confirm
enhanced neurotoxicity of truncated tau in an animal model.
Intriguingly, C-terminally truncated tau has also been reported in
other tauopathies including Pick’s disease, corticobasal degener-
ation and progressive supranuclear palsy [32], and even possibly in
other neurodegenerative diseases, including Parkinson’s disease
and related synucleinopathies [62]. Together, these data suggest
that C-terminally truncated tau may be an important effector of
neurotoxicity in tauopathies and possibly other neurodegenerative
conditions.
Like tau aggregation, lysosomal dysfunction is also feature of a
diverse group of neurodegenerative diseases [6]. We have focused
on the evidence for lysosomal dysfunction in Alzheimer’s disease
thus far in the current report, but lysosomal dysfunction has been
suggested in other disorders, including Parkinson’s disease,
amyotrophic lateral sclerosis, prion diseases, and even in models
of traumatic brain injury [6,63]. Indeed, lysosomal storage
diseases, in which severe and often early onset neurodegeneration
is caused by mutations in lysosomal protein-encoding genes,
suggest that postmitotic neurons are dependent on normal
lysosomal function [1]. In this study we establish a link in vivo,i n
the setting of cathepsin D removal, between lysosomal dysfunction,
caspase activation and tau truncation. We further suggest a similar
relationship in mammalian systems because we show activated
caspase and formation of caspase-cleaved tau in cathepsin D null
mice and sheep, both well-established models of neuronal ceroid
lipofuscinosis [42,43].
In summary, the data outlined in this study have suggested
causal connections in vivo between lysosomal dysfunction and
neurodegeneration in a model of Alzheimer’s disease and other
tauopathies. Our data support a scenario in which normal levels of
cathepsin D are required for proper lysosomal function, and in
which caspase cleavage of tau is a a neurotoxic effector of
lysosomal dysfunction in these diseases. A link between the
lysosomal system and tau fragmentation has been supported by
recent work from the Mandelkow laboratory as well [64]. We
speculate that lysosomal dysfunction and subsequent caspase-
mediated cleavage of tau may be common mechanisms of
neurodegeneration in a diverse number of diseases, and attractive
targets for therapeutic intervention.
Materials and Methods
Transgenic Drosophila
Flies were grown on standard cornmeal medium at 25uC. UAS-
tau
1–421 flies were created by introducing a stop codon following
residue 421 in the human wild-type tau cDNA. A 0 N-terminal
insert, 4 microtubule binding repeat (0N4R) form of tau was used
in all experiments. The tau
1–421 mutant cDNA was cloned into the
GAL4-responsive pUAST expression vector. Transgenic strains
were created by embryo injection. Ten independent transgenic
lines were obtained and analyzed. The UAS-SCA3 [25,26], UAS-
tau
WT, UAS-tau
R406W [19], and cathD
1 mutant [22] stocks have
been previously described. The panneural elav-GAL4 driver was
obtained from the Bloomington Drosophila Stock Center (Bloo-
mington, IN) and was used in all experiments. The Cp1-GFP
(ZCL2854) flies were obtained from W. Chia [65] via L. Cooley.
Lifespan analysis was performed as described previously [19].
Briefly, flies were aged in groups of no more than 25 flies per vial.
Culture medium was changed every 2 days and the number of
dead flies recorded. At least 300 flies were aged for each genotype.
RNA isolation, quantitative PCR, and quality controls were
previously described [21]. Briefly, RNA was isolated from heads of
flies aged to 1, 10, or 30 days, quantitative PCR was performed
using the Comparative CT method and GAPDH as reference
gene. Approximately equal amplification efficiencies of target and
reference gene were previously confirmed [21].
Immunohistochemistry and histology
Adult flies or mouse or sheep brain tissue was fixed in formalin
and embedded in paraffin. Brains from three cathepsin D knockout
mice were examined (two postnatal day (P) 20, one P24), and from
three controls (two P20, one P24). Tissue from three cathepsin D
deficient sheep and two control sheep was examined. Sheep were
one day old. For Drosophila tissue, serial frontal sections (4 mm)
were made of the entire brain. To assess general brain
morphology, vacuolar degeneration, and Kenyon cell density,
sections were stained with hematoxylin and eosin. Vacuolar
degeneration was assessed by counting vacuoles larger than 3 mm
in at least six hemibrains per genotype. To evaluate Kenyon cell
loss in the ataxin 3 model, the number of cells in a defined 35 mm
area in well-oriented frontal sections was counted. At least six
hemibrains were counted per genotype.
For immunostaining, antigen retrieval was performed by
microwaving in sodium citrate (pH 6.0) for 15 minutes. The
primary antibodies used were tau-C3 (1:1,000, Biosource), PCNA
(1:100, Biomeda), and activated Caspase-3 (1:250, Trevigen).
Secondary detection was performed with an avidin-biotin-
peroxidase complex (ABC) method (Vector Laboratories) or with
secondary antibodies coupled to Alexa Fluor 488 or Alexa Fluor
555. For quantitation of PCNA staining, the number of PCNA-
positive foci was counted in at least 6 brains per genotype.
TUNEL analysis
Brain sections from 10-day-old flies were stained using the
TUNEL assay (TdT FragEL DNA fragmentation kit; EMD
Biosciences) and the avidin-biotin-peroxidase complex (ABC)
detection method (Vectastain ABC Kit; VectorLaboratories).
Quantification of TUNEL-positive foci was performed on at least
six hemibrains (Figure 1) or six whole brains (Figure 5) per
genotype.
Western blot and tau solubility analysis
Heads from 10 day-old-adult Drosophila were homogenized in
Laemmli buffer, resolved by SDS-PAGE and immunoblotted as
indicated. The primary antibodies used were rabbit polyclonal
anti-tau (1:10
6, Dako), tau-C3 (1:1,000, Biosource), anti-actin
(1:50,000, Sigma-Aldrich), AT8 (1:50,000, Pierce Biotechnology),
TG3 (1:1,000, P. Davies, Albert Einstein College of Medicine,
Bronx, New York, USA), PHF1 (1:50,000, P. Davies), AT180
(1:2,000, Pierce Biotechnology), and AT270 (1:10,000, Pierce
Biotechnology). The polyclonal antibody against tau from Dako
recognizes sequences near the microtubule binding domain and
was used to assess levels of total tau in Figure 2, Figure 3, Figure 5,
Figure S4. Secondary antibodies conjugated to HRP (South-
ernBiotech) were used at 1:50,000 dilution, and signal detection
was performed with chemiluminescence (Pierce Biotechnology).
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were repeated at least three times with similar results.
Nonionic detergent-soluble and -insoluble protein fractions
were prepared by homogenization of fly heads in TNE buffer
(10 mM Tris-HCl, pH 7.4; 150 mM NaCl; 5 mM EDTA)
containing protease inhibitors (Roche Complete Protease Inhibitor
Cocktail) and detergents (0.5% Nonidet P-40), as previously
described [66]. The homogenate was centrifuged (5 min at
100,0006g), and the resulting pellet and supernatant fractions
were collected. The pellet was washed once in TNE containing
nonionic detergents, and the resulting pellet (nonionic detergent-
insoluble) was solubilized in TNE buffer containing 1% SDS.
Equivalent amounts of soluble and insoluble material from tau
WT
and tau
1–421 homogenates were loaded to ensure accurate
comparisons between the two genotypes.
Lysosome analysis
In order to visualize lysosomal morphology, fresh whole mount
brains from 10 day-old flies were incubated with 100 mM
lysotracker for 5 minutes, mounted in PBS, and analyzed with a
Zeiss laser-scanning confocal microscope.
Supporting Information
Figure S1 Cathepsin D is overexpressed in tau-transgenic flies at
early and advanced disease-stages. Relative cathepsin D mRNA
abundance is 1.6-fold and 2-fold elevated in 10-day-old and 30-
day-old tau transgenics compared to age-matched control animals
using quantitative PCR (***P=0.005 and **P=0.037), consistent
with our microarray screen [21].
Found at: doi:10.1371/journal.pgen.1001026.s001 (0.11 MB TIF)
Figure S2 No change in the neurotoxicity of mutant ataxin 3 in
the absence of cathepsin D. Expression of expanded ataxin 3
(MJD) produces significant loss of Kenyon cells, and that loss is not
exacerbated by removing cathepsin D. Flies are 10 days old.
Control is elav-GAL4/+.
Found at: doi:10.1371/journal.pgen.1001026.s002 (0.28 MB TIF)
Figure S3 Specificity of tau-C3 in immunofluorescence analysis.
(A) There is no tau-C3 immunoreactivity in control flies (genotype:
elav-GAL4/+). (B) Immunoreactivity for tau-C3 is present in
selected neurons in flies expressing tau (genotype: elav-GAL4/
+;UAS-tau-R406W/+). (C) Widespread tau-C3 immunoreactivity is
present in brains of flies expressing C-terminally truncated tau
(genotype: elav-GAL4/+;UAS-tau-1-421/+). Sections were cut,
processed, immunostained, and imaged in parallel. Imaging
conditions (including time of camera exposure) were held constant
for panels A and B, but a weaker exposure of C is shown to allow
appreciation of cellar detail. Flies are 10 days old.
Found at: doi:10.1371/journal.pgen.1001026.s003 (1.27 MB
TIF)
Figure S4 Specificity of tau-C3 immunostaining in Western
blotting analysis. Homogenates from control flies (genotype: elav-
GAL4/+) and flies expressing C-terminally truncated tau (geno-
type: elav-GAL4/+;UAS-tau-1-421/+) were run on the same gel in
the order indicated. The gel was then cut in half as indicated by
the dotted line and hybridized with the tau-C3 monoclonal
antibody (left) or a polyclonal antibody recognizing tau (anti-tau,
Dako, right). The blot was reprobed with an antibody recognizing
actin to evaluate protein loading. Flies are 10 days old.
Found at: doi:10.1371/journal.pgen.1001026.s004 (0.12 MB
TIF)
Figure S5 Soluble fractions from flies expressing wild-type tau
and C-terminally truncated tau. The entire molecular weight
range, together with molecular weight markers in KDa is shown
for the blot in Figure 5C.
Found at: doi:10.1371/journal.pgen.1001026.s005 (0.07 MB
TIF)
Figure S6 Insoluble fractions from flies expressing wild-type tau
and C-terminally truncated tau. The entire molecular weight
range, together with molecular weight markers in KDa is shown
for the blot in Figure 5D.
Found at: doi:10.1371/journal.pgen.1001026.s006 (0.19 MB
TIF)
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